41 – 50 of 62
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2013
-
Mark
Clinical Impact of 2-Deoxy-2-[18F]fluoro-D-Glucose (FDG)-Positron Emission Tomography (PET) on Treatment Choice in Recurrent Cancer of the Cervix Uteri.
- Contribution to journal › Article
- 2011
-
Mark
Two-year results from a Swedish study on conventional versus accelerated radiotherapy in head and neck squamous cell carcinoma The ARTSCAN study
- Contribution to journal › Article
- 2010
-
Mark
Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma
- Contribution to journal › Article
-
Mark
Early Metabolic Flare in Squamous Cell Carcinoma after Chemotherapy is a Marker of Treatment Sensitivity In Vitro
- Contribution to journal › Article
- 2009
-
Mark
Prediction of patient outcome with 2-deoxy-2-[18F]fluoro-D-glucose-positron emission tomography early during radiotherapy for locally advanced cervical cancer.
- Contribution to journal › Article
-
Mark
Comparison of cisplatin sensitivity and the 18F fluoro-2-deoxy 2 glucose uptake with proliferation parameters and gene expression in squamous cell carcinoma cell lines of the head and neck
- Contribution to journal › Article
-
Mark
Early changes in 2-deoxy-2-[18F]fluoro-D-glucose metabolism in squamous-cell carcinoma during chemotherapy in vivo and in vitro.
- Contribution to journal › Article
- 2007
-
Mark
2-deoxy-2-[F-18]fluoro-D-glucose uptake and correlation to intratumoral heterogeneity
- Contribution to journal › Article
-
Mark
Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck
- Contribution to journal › Article
-
Mark
FDG-PET in cervical cancer: staging, re-staging and follow-up.
- Contribution to journal › Article
